OTCMarkets UPDATE: DiaMedica Therapeutics, Choom Holdings and more

DiaMedica shares jumped after announcing positive results from an FDA meeting

Stock charts
Shares of Choom were up after an acquisition completion

The OTCMarkets were mixed on Thursday, with the OTCQX US and Canada seeing slight gains.

Shares of DiaMedica Therapeutics Inc (OTCQB:DMCAF) were up more than 5% to US$0.42 after announcing positive results from a U.S. Food and Drug Administration meeting regarding planned clinical trials for patients with chronic kidney disease. The Minneapolis-based biopharmaceutical company develops treatments for neurological and kidney diseases.

READ: First Cobalt Corp assays broad zones of mineralisation at Canadian Cobalt Camp

First Cobalt Corp (OTCQX:FTSSF) announced that recent drilling results show that the strike length has doubled to 200 meters in the Kerr area’s mineralized zone. Shares of the Toronto-based company were up nearly 4% to US$0.59.

High Hampton Holdings (OTCMKTS:HHPHF, CSE:HC) has received approval from the Coachella City Planning Commission for cannabis farming. The area was made famous by the namesake music festival, which has featured mega stars like Beyonce and Eminem. Shares were up nearly 5% to US$0.87.

Cannabis company Choom Holdings Inc’s (OTCQB:CHOOF) shares jumped nearly 3% to US$0.71 after announcing that it had completed its acquisition of Island Green Cure Ltd, an advanced-stage cannabis production license applicant. Based in Vancouver, the company develops recreational cannabis products for sale in its retail stores.

Aequus Pharmaceuticals Inc (OTCQB:AQSZF) reported positive feedback from the FDA on its anti-nausea patch, or AQS1303. The Vancouver-based company develops treatments for neurologic and psychiatric disorders and is working to add medicinal cannabis to its portfolio. Shares were down around 2% to US$0.22.

Quick facts: DiaMedica

Price: - CAD

Market: TSX-V
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Faron Pharma CEO confident as he looks ahead to new Traumakine study

Faron Pharmaceuticals Oy (LON:FARN) (FIRSTNORTH:FARON) CEO Dr Markku Jalkanen caught up with Proactive London's Andrew Scott soon after announcing they've amended the protocol for a second phase III study of its drug for acute respiratory distress syndrome (ARDS). The tweak's in response to...

9 hours, 42 minutes ago

2 min read